NCT03803215View on ClinicalTrials.gov

Theophylline for Low Adenosine Syncope

CompletedOBSERVATIONAL
Enrollment

77

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

November 30, 2020

Study Completion Date

December 30, 2020

Conditions
Syncope
Interventions
DRUG

Theophylline

Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose

Trial Locations (1)

16033

Department of Cardiology, Ospedali del Tigullio, Lavagna

All Listed Sponsors
collaborator

Gruppo Italiano Multidisciplinare per lo Studio della Sincope

OTHER

lead

Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella

OTHER

NCT03803215 - Theophylline for Low Adenosine Syncope | Biotech Hunter | Biotech Hunter